OPEN ACCESS

ISSN: 2835-9496

Herrick G, et al. (2025): 813
Ameri J Clin Med Re, 2025; 5(1): 100183
DOI: 10.71010/AJCMR.2025-e183

Research Article

American Journal of Clinical and Medical Research

Optimizing Antimicrobial Therapy in Purpura Fulminans-Associated Sepsis: Critical Care Considerations

Grace Herrick, BA[1], Mahnoor Mukarram, MS[2], Kelly Frasier, DO, MS[3*], Darianne Zimmer, BS[4], Haily Fritts, BS[5], Zachary Grand, BS[6], Sriya Kakarla, BA[7]

[1]Alabama College of Osteopathic Medicine, Dothan, AL
[2]Midwestern University Arizona College of Osteopathic Medicine, Glendale, AZ
[3]Department of Dermatology, Northwell Health, New Hyde Park, NY
[4]University of California, Riverside School of Medicine, Riverside CA
[5]Idaho College of Osteopathic Medicine, Meridian, ID
[6]Florida International University Herbert Wertheim College of Medicine, Miami, FL
[7]UTHealth Houston, McGovern Medical School, Houston, TX

Abstract

Purpura fulminans, a rare but life-threatening manifestation of disseminated intravascular coagulation, presents a formidable challenge in critical care settings, particularly when complicated by sepsis. Past research has underscored the crucial role of timely and appropriate antimicrobial therapy in mitigating mortality and morbidity in purpura fulminans-associated sepsis. However, gaps persist in our understanding of the optimal selection, dosing, and duration of antimicrobial agents in this context. This review examines existing literature on antimicrobial therapy in purpura fulminans-associated sepsis, highlighting advancements in antimicrobial pharmacokinetics, pathogen susceptibility patterns, and the evolving landscape of antimicrobial resistance. Additionally, it discusses emerging strategies such as combination antimicrobial therapy, adjunctive therapies targeting virulence factors, and antimicrobial stewardship interventions aimed at optimizing antimicrobial use while minimizing collateral damage. Future research directions include prospective studies evaluating personalized antimicrobial regimens guided by pharmacokinetic/pharmacodynamic principles, the role of novel antimicrobial agents, and the impact of antimicrobial therapy on long-term outcomes such as antimicrobial resistance and microbiome dysbiosis. Moreover, the integration of rapid diagnostic technologies and biomarker-guided approaches holds promise for tailoring antimicrobial therapy to individual patient characteristics and disease severity, ultimately enhancing clinical outcomes in purpura fulminans-associated sepsis within critical care settings.

***Corresponding author:**

Kelly Frasier, DO, MS, Department of Dermatology, Northwell Health, New Hyde Park, NY. Email: kellymariefrasier@gmail.com

Citation: Herrick G, Mukarram M, Frasier K, Zimmer D, Fritts H, et al. (2025) Optimizing Antimicrobial Therapy in Purpura Fulminans-Associated Sepsis: Critical Care Considerations. J Clin Med Re: AJCMR-183.

Received Date: 03 January, 2025; **Accepted Date:** 17 January, 2025; **Published Date:** 23 January, 2025

Introduction

Purpura fulminans (PF) is a rare yet life-threatening disorder marked by disseminated intravascular coagulation (DIC) and hemorrhagic skin infarctions. This condition rapidly progresses to multi-organ failure due to the widespread thrombotic occlusion of small and medium-sized blood vessels [1]. Bacterial infections, particularly *Neisseria meningitidis* and *Streptococcus pneumoniae*, are common triggers of PF, though other pathogens, including *Streptococcus pyogenes* and *Capnocytophaga canimorsus* have also been implicated [2,3]. PF may also occur in response to viral infections, autoimmune reactions, or congenital deficiencies in natural anticoagulants like protein C and protein S [4]. Given the aggressive nature of purpura fulminans, early recognition and prompt intervention are vital for improving outcomes.

Clinically, purpura fulminans presents with erythematous macules, which quickly evolve into necrotic purpuric lesions, reflecting underlying microvascular thrombosis. This rapid progression is a hallmark that distinguishes PF from other purpuric conditions [5]. The pathophysiology of PF involves a complex interaction between systemic inflammation and coagulopathy, exacerbated by protein C deficiency, a key regulator of thrombin generation [6]. Such abnormalities often manifest in pediatric populations, especially in cases of severe sepsis. Approximately 10-20% of meningococcal septicemia cases are complicated by PF, highlighting the importance of bacterial infections in its etiology [4].

The mortality rate for purpura fulminans remains high, often exceeding 40%, despite aggressive interventions [7]. Rapid progression to multi-organ dysfunction syndrome is frequently observed due to widespread microthrombosis [8]. Survivors of PF frequently suffer significant long-term morbidity, including amputations and chronic organ dysfunction from extensive tissue necrosis. While predominantly seen in children, PF can also affect adults, especially those with atypical immune responses to systemic infections [9]. These outcomes underscore the critical importance of early recognition and the need for multidisciplinary management of purpura fulminans.

Purpura fulminans is closely linked to DIC, a systemic process of coagulation activation that leads to widespread fibrin deposition, clotting factor depletions, and microthrombosis [10]. PF represents an extreme manifestation of this condition, affecting skin and subcutaneous tissues, often exacerbated by severe protein C deficiency. The pathogenesis of PF, driven by infection-induced systemic inflammation coupled with

coagulation abnormalities, represents significant challenges for clinical management [11]. Understanding these mechanisms is essential for developing targeted therapeutic strategies for purpura fulminans.

Managing purpura fulminans in the critical care setting remains a formidable challenge due to its rapid progression and high mortality rate. Patients often present in septic shock, necessitating immediate hemodynamic stabilization, administration of antibiotics. Coagulation support, including fresh frozen plasma or protein C concentrates is often required to mitigate the underlying coagulopathy. Advanced supportive care, such as mechanical ventilation and renal replacement therapy, may be necessary to address complications, yet outcomes remain poor [11]. These challenges highlight the need for further research into more effective therapies for purpura fulminans.

Discussion

Historical Context and Significance of Antimicrobial Therapy

Antimicrobial therapy has long been central to the treatment of sepsis and purpura fulminans, drastically reducing mortality rates in what were once universally fatal infections. The introduction of antibiotics, especially penicillin during World War II, marked a pivotal moment in medical history by halting the progression of infection and systemic inflammatory responses, especially among soldiers suffering from severe bacterial infections [12]. This era saw a dramatic decline in infection-related deaths, underscoring the critical role of early, broad-spectrum antibiotic use in managing severe infections. Dr. Maxwell Finland's pioneering work in the mid-20th century further shaped the modern landscape of sepsis management [13]. His research laid the foundation for empirical antibiotic therapy, promoting the rapid administration of broad-spectrum antibiotics to combat sepsis and PF-associated infections. Finland also foresaw the emerging threat of antimicrobial resistance, an issue that remains at the forefront of public health challenges today. His research was instrumental in developing clinical guidelines advocating for the prompt treatment of severe infections and in establishing regulatory frameworks for the approval of new antibiotics based on rigorous clinical trials [13,14].

However, despite the early successes of antibiotic therapy, antibiotic resistance quickly became a global threat, complicating the treatment of sepsis. Today, the Centers for Disease Control and Prevention (CDC) reports that over 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in more than 35,000 deaths [15]. These alarming statistics underscore the need for continued vigilance and innovation to preserve the efficacy of sepsis treatments. Early research into combination antibiotic therapy, such as the use of penicillin and aminoglycosides, aimed to expand coverage and exploit synergistic effects, especially in high-risk populations like cancer patients with febrile neutropenia [16]. However, with the development of potent broad-spectrum antibiotics, monotherapy became more common. Unfortunately, the emergence of multi-resistant microorganisms necessitates a return to combination therapy to maintain efficacy in sepsis management [16].

The role of pharmacokinetic (PK) and pharmacodynamic (PD) principles has become critical in optimizing antimicrobial therapy. PK studies focus on the time course of drug absorption, distribution, metabolism, and excretion, while PD studies assess the relationship between drug concentrations and their effects [17]. These methods allow for more precise dosing regimens, minimizing toxicity and improving therapeutic outcomes. Recent advancements in PK-PD methodologies, such as population PK modeling and Monte Carlo simulations, have revolutionized drug development [17]. These methods allow for the optimization of dosing regimens and tailoring therapies to specific patient populations, including those critically ill with purpura fulminans.

The historical significance of antimicrobial therapy in treating sepsis and purpura fulminans highlights the critical need for continuous adaptation. Finland's work laid the groundwork for empirical antibiotic use, while subsequent advances in combination therapies and PK-PD studies have further refined treatment approaches. However, the persistent rise of antimicrobial resistance demands that we leverage both historical insights and modern innovations to develop targeted, effective treatments for purpura fulminans-associated sepsis.

Optimal Selection of Antimicrobial Agents

Selecting the optimal antimicrobial agent for the treatment of purpura fulminans-associated sepsis is challenging due to the complexity of the condition and the growing threat of antimicrobial resistance. Current guidelines recommend broad-spectrum agents for initial empiric therapy, but emphasize the importance of de-escalating to a more targeted therapy based on local resistance patterns and prior antibiotic use [18]. A recent cross-sectional study of 6.3 million adults in United States hospitals between 2017 and 2021 highlighted the overuse of broad-spectrum antibiotics, finding that while anti-methicillin-resistant *Staphylococcus aureus* (MRSA) and antipseudomonal β-lactam agents were prescribed in half of the suspected sepsis cases, only 9.5% of cases involved resistant organisms [18]. This overuse not only fosters resistance but also exposes patients to unnecessary drug-related toxicities. The study also noted that broad-spectrum antibiotic use for suspected sepsis increased over time, while the proportion of cases with proven resistant infections decreased, highlighting a growing mismatch between empiric prescribing and actual pathogen resistance profiles [18]. This underscores the critical need for improved antibiotic stewardship to balance early treatment with the risks associated with overuse.

To improve outcomes, it is critical to match the chosen antimicrobial agent with the specific pathogen involved and to optimize dosage regimen. PK-PD analyses are invaluable in this regard, particularly for patients with altered physiology due to organ dysfunction, fluid shifts, or systemic inflammation, which are common in critical illnesses like PF [17]. Therapeutic drug monitoring (TDM) further aids in this process by measuring drug concentrations in the blood to ensure effective yet safe dosing, particularly in cases with unpredictable pharmacokinetics to allow clinicians to tailor the dose of an antimicrobial agent to ensure a minimum reliable concentration to combat the infection while minimizing toxicity [19]. TDM helps clinicians adjust dosing to maintain drug levels within the therapeutic window, optimizing both efficacy and safety in treating purpura fulminans-associated sepsis.

Recent studies have highlighted the potential of abbreviated antibiotic regimens, particularly when combined with early source control and rapid diagnostics. Studies suggest that shorter courses of antibiotics can be effective, provided they are administered promptly [20]. Delays in antibiotic initiation increased the risk of progression to septic shock by 4% per hour, emphasizing the need for timely intervention [20]. However, the optimal length of therapy for PF-associated sepsis remains uncertain. The heterogeneity of sepsis cases and the variability in pathogen profiles makes it difficult to establish uniform treatment guidelines. Further research is needed to establish evidence-based recommendations that balance the benefits of adequate antimicrobial exposure with the risks of prolonged therapy, ensuring the best outcomes for patients with purpura fulminans-associated sepsis.

Advances in Antimicrobial Pharmacokinetics

Recent advancements in antimicrobial pharmacokinetics have become crucial in treating critically ill patients, particularly those with purpura fulminans-associated sepsis. The physiological alterations seen in these patients—ranging from impaired organ function to significant fluid shifts—can dramatically alter drug absorption, distribution, metabolism, and elimination [21]. Standard dosing regimens often fail in such environments, leading to subtherapeutic concentrations or drug toxicity. To address these challenges, PK-PD models and TDM have become essential tools for individualizing treatment [22]. These approaches ensure that drug concentrations are maintained within the therapeutic window, optimizing the balance between efficacy and safety, offering a more tailored approach to treatment [23]. The application of these methodologies, especially in critical care environments, has made it possible to minimize adverse effects while ensuring adequate therapeutic response.

In PF, where patients are susceptible to rapid multi-organ failure and coagulopathy, individualized dosing becomes even more critical. The disease's microvascular thrombosis can further complicate drug pharmacokinetics, necessitating precise adjustments to prevent both under- and over-dosing. Techniques like continuous or extended infusions of antibiotics, such as beta-lactams, have shown efficacy in maintaining stable drug concentrations. These methods reduce dosing fluctuations and have been associated with improved outcomes in critically ill patients [24]. Moreover, integrating PK-driven dosing with advanced diagnostic technologies, such as real-time pathogen profiling, allows for even greater precision in managing purpura-fulminans-associated sepsis, ensuring treatments are both timely and targeted [23].

Pathogen Susceptibility Patterns

Pathogen susceptibility patterns play a critical role in guiding antimicrobial therapy, particularly in sepsis associated with purpura fulminans. Historically, common pathogens implicated include *Streptococcus pneumoniae, Neisseria meningitidis*, and *Staphylococcus aureus*, with increasing resistance complicating treatment decisions [**25**]. For instance, resistance to penicillin and cephalosporins has limited their efficacy in empirical therapy, especially with the rise of MRSA, requiring more potent agents like vancomycin or linezolid [**26**]. These shifts in susceptibility patterns have underscored the need for continuous monitoring and adaptive treatment protocols to ensure that empirical therapies remain effective against emerging resistant strains.

Advances in rapid diagnostics have revolutionized the identification of causative pathogens, allowing for more accurate and timely adjustments to antimicrobial therapy. Techniques such as polymerase chain reaction (PCR) enable the detection of pathogens even when standard bacterial cultures are negative, providing critical information that can guide targeted therapies [27]. This is especially important in PF, where rapid pathogen identification can minimize delays in treatment and reduce the use of ineffective antibiotics. When combined with PK-PD models, these diagnostics allow for antimicrobial therapy that is not only pathogen-specific but also dosed appropriately for each patient's unique physiology [28]. Ultimately, this reduces the likelihood of treatment failure due to inadequate dosing or resistance

Antimicrobial Resistance

The rise of antimicrobial resistance (AMR) presents a significant challenge in the management of sepsis, particularly in severe cases like purpura fulminans. Multidrug-resistant organisms, including MRSA and extended-spectrum beta-lactamase (ESBL)-producing bacteria, have complicated treatment strategies, often necessitating the use of more toxic second-line agents like colistin [26,29]. Resistance among Gram-negative bacteria has also increased, leading to a growing reliance on combination therapies or last-resort antibiotics. This situation highlights the importance of antimicrobial stewardship programs that focus on optimizing antibiotic use and preventing the further spread of resistance.

One of the most critical elements of sepsis management in the context of AMR is the timely administration of effective empiric therapy. Inappropriate or delayed treatment significantly increases mortality, especially when resistant pathogens are involved [28]. Antimicrobial stewardship programs guide the early use of broad-spectrum antibiotics, followed by de-escalation to narrower-spectrum agents once susceptibility data are available. This approach helps balance the need for immediate, effective treatment with the goal of preserving the efficacy of existing antibiotics for future use. Additionally, combining rapid diagnostic tools with PK-PD models enhances antimicrobial precision, allowing for real-time adjustments to dosing regimens that align with pathogen-specific profiles [26,27]. This synergy between stewardship, diagnostics, and individualized dosing ensures that therapy remains effective without contributing unnecessarily to resistance development.

Rapid Diagnostic Technologies

Recent advances in rapid diagnostic technologies have transformed the identification of pathogens and their resistance profiles, offering faster and more comprehensive diagnostic capabilities. Key technologies include rapid diagnostic tests (RDTs), which provide point-of-care detection of specific antigens or antibodies; polymerase chain reaction (PCR), which amplifies DNA sequences of pathogens; and mass spectrometry, such as which identifies microorganisms by their proteome profiles. These tools are especially critical for patients suffering septicemia in PF. Incorporating these technological innovations into antimicrobial therapy can significantly enhance the precision and efficacy of treatment.

RDTs, in particular, hold immense potential for refining antibiotic selection in purpura fulminans and other forms of sepsis. As highlighted by Moore et al., these tests have been recommended for inclusion in the World Health Organization (WHO) Model List of essential in vitro diagnostics due to their

capacity to improve outcomes through more targeted antimicrobial choices [30]. However, global integration remains a challenge, particularly in lower- and middle-income countries where access to such assays is variable. Ensuring the widespread availability, affordability, and ease of use of these technologies is essential for their adoption into routine clinical practice.

PCR-based technologies have also revolutionized the speed of pathogen identification. In critical care settings, studies have shown that PCR panels can deliver results within hours, substantially faster than traditional culture methods. For example, a study by Garrido et al.demonstrated that multiplexed PCR panels improved diagnostic efficacy in sepsis secondary to pneumonia, leading to more appropriate antibiotic adjustments in over 70% of cases involving bloodstream infections [31]. This highlights how PCR data can guide more appropriate antibiotic selection compared to empiric therapy alone. Furthermore, emerging technologies such as SepsiTest and SeptiFast further enhance pathogen detection, and when integrated with machine learning algorithms, they offer improved diagnostic accuracy and predictive insights for patient outcomes [32]. Applications of these tools in critical care settings, such as purpura fulminans-related sepsis, could improve outcomes by ensuring timely and accurate treatment adjustments.

Mass spectrometry, particularly MALDI-TOF, has also gained prominence in clinical microbiology due to its ability to rapidly identify a broad spectrum of pathogens. A review by Luethy and Johnson highlighted its efficiency, noting that mortality rates decreased by 4-9% when MALDI-TOF was used for pathogen identification [33]. Additionally, when combined with antimicrobial stewardship programs, MALDI-TOF has been shown to reduce the time to effective antimicrobial therapy by 4.6 hours and the time to optimal therapy by over 30 hours, leading to improved outcomes and cost savings [33]. The integration of this technology into critical care settings managing purpura-fulminans-associated sepsis could accelerate appropriate treatment, shorten hospital stays, and reduce the need for extensive diagnostic testing. This efficiency translates into substantial financial savings for healthcare systems.

The advantages of rapid diagnostic technologies in early pathogen detection and antimicrobial stewardship are numerous. By enabling early, accurate identification of the causative pathogens, these tools facilitate more targeted antimicrobial therapy, which can significantly improve patient outcomes. Additionally, rapid diagnostics help clinicians adhere to stewardship principles by minimizing unnecessary antimicrobial use, thus preserving the efficacy of existing antibiotics. Beyond their clinical applications, these technologies also have broader public health implications, particularly in the early detection of outbreaks and the identification of emerging pathogens. Nevertheless, the sensitivity and specificity of rapid diagnostics must continue to improve through ongoing research. Efforts to make these technologies more accessible and affordable in diverse clinical settings, alongside training for healthcare professionals, will be crucial for their successful implementation. Investment in infrastructure, training, and legislative support will help ensure that these technologies become integral to the management of sepsis, particularly in cases as severe as purpura fulminans.

Biomarker-Guided Approaches

Biomarkers are essential tools in modern medicine, acting as measurable indicators of biological processes that can guide therapeutic decisions.In the context of sepsis and purpura fulminans, biomarkers provide valuable information about the presence of infection and the host's immune response. Common biomarkers like procalcitonin (PCT), C-reactive protein (CRP), serum amyloid A (SAA), and interleukin-6 (IL-6), are frequently studied for their role in infection management.These biomarkers help clinicians tailor antimicrobial therapies more effectively, reducing the risks of both overtreatment and undertreatment in critically ill patients.

Procalcitonin has emerged as one of the most promising biomarkers for guiding antibiotic therapy, particularly in bacterial infections. Monitoring PCT levels can help clinicians decide when to initiate or discontinue antibiotics, ultimately supporting antimicrobial stewardship efforts. Studies have shown that using PCT-guided algorithms reduce unnecessary antibiotic use without compromising patient outcomes [34,35]. Qu et al. further highlighted PCT's predictive superiority over CRP, IL-6, or SAA in critical care settings [34]. Although CRP and IL-6 also play a role in identifying bacterial infections, PCT has consistently demonstrated greater diagnostic value. However, some studies, such as Lee et al., emphasize that high IL-6 levels can occasionally coincide with normal or low CRP and PCT levels, potentially leading to underdiagnosis if IL-6 is not measured [35]. The integration of multiple biomarkers such as PCT, CRP, and IL-6 into clinical protocols can significantly enhance the precision of antimicrobial therapy. This approach allows for more tailored treatment decisions, particularly in severe conditions like purpura fulminans-associated sepsis. While PCT alone has shown strong predictive value, combining it with other biomarkers ensures a more nuanced assessment of the patient's inflammatory and infectious status. As diagnostic technologies continue to evolve, the incorporation of these biomarkers-guided strategies into routine clinical practice will be vital for improving patient outcomes, particularly in complex, life-threatening infections.

Biomarker-guided approaches offer significant benefits in sepsis management.Studies have shown that biomarker-based diagnostics can decrease time to adequate treatment, reduce mortality, and shorten hospital stays, all while enhancing antimicrobial stewardship [34,35]. By minimizing the unnecessary use of broad-spectrum antibiotics, clinicians can adhere to precision medicine principles, ensuring that treatment is tailored to the specific pathogen and patient condition. In addition to their role in individual patient management, biomarkers also have broader implications for public health by enabling earlier detection of outbreaks and resistant bacterial strains. As these technologies continue to evolve, continued research will be essential to enhance their sensitivity and specificity, expanding their access across diverse healthcare settings.

Emerging Strategies in Antimicrobial Therapy

Combination Antimicrobial Therapy

The complexity and severity of sepsis, particularly in purpura fulminans, often necessitate the use of combination antimicrobial therapy. This strategy provides broader-spectrum coverage, targeting pathogens simultaneously and improving bacterial clearance. The rationale behind combination therapy lies not only in its ability to address polymicrobial infections but

also in overcoming bacterial virulence mechanisms like biofilm formation and toxin production, which are common in severe sepsis [36]. Furthermore, combination therapy may reduce the development of antibiotic resistance, especially in cases where monotherapy is insufficient to control highly virulent or resistant pathogens.

In critical care settings, combination therapy has demonstrated improved outcomes in severe sepsis and septic shock. Kumar et al. found that the use of beta-lactams combined with aminoglycosides, fluoroquinolones, or macrolides significantly decreased 28-day mortality rates compared to beta-lactam monotherapy [37,38]. These findings highlight the importance of initiating broad-spectrum combination therapy early, particularly when blood cultures are pending and the source of infection is unclear [39]. This approach is especially relevant in purpura fulminans, where the overwhelming inflammatory response and coagulopathy necessitate rapid pathogen clearance to prevent further vascular damage and tissue necrosis.

The efficacy of combination antimicrobial therapy has been further supported by large-scale studies. For instance, a retrospective cohort study involving 28 intensive care units demonstrated that early combination therapy in septic shock was associated with improved survival and increased ventilator-free days [37]. These findings demonstrate the importance of prompt, aggressive combination antimicrobial therapy in critically ill patients, especially those with life-threatening infections such as purpura fulminans. While combination therapy offers substantial benefits, its use should be guided by local resistance patterns and patient-specific factors to minimize toxicity and resistance development. Ongoing research into the optimal antibiotic combinations and treatment durations will be essential to further refine this approach.

Adjunctive Therapies Targeting Virulence Factors

In addition to traditional antimicrobial therapies, adjunctive treatments targeting bacterial virulence factors represent a promising area of innovation in purpura fulminans-associated sepsis. These therapies focus on inhibiting the mechanisms bacteria use to evade the immune system, produce toxins, or form biofilm formation. By interfering with these virulence mechanisms, anti-virulence therapies have the potential to reduce the severity of infection without promoting antibiotic resistance, which is a major advantage in critical care settings [40]. Incorporating anti-virulence therapies into existing treatment protocols may significantly enhance patient outcomes in purpura fulminans-associated sepsis.

One promising area involves therapies targeting the secretion of bacterial toxins, such as those produced by *Staphylococcus aureus*, which contribute to endothelial damage and the coagulopathy seen in purpura fulminans. Additionally, agents that disrupt biofilms or enhance host immune responses, such as monoclonal antibodies or immune modulators, may aid in pathogen clearance and reduce systemic inflammation [41]. Another promising approach involves the use of quorum-sensing inhibitors, which block chemical communication pathways involved in toxin production and biofilm formation. This is particularly relevant in biofilm-associated infections, such as central line-associated bloodstream infections (CLABSIs), that can complicate the management of PF patients [41]. By reducing infection severity without promoting antibiotic resistance, these adjunctive therapies offer a promising path forward in managing complex infections in critically ill patients.

In critical care, adjunctive therapies that target virulence factors could mitigate the severity of septic shock and reduce organ damage. Combining multiple anti-virulence agents to target different bacterial mechanisms has been shown to produce a synergistic effect, rendering combination therapy an effective strategy for improving patient outcomes [41]. While these therapies are still largely experimental, preliminary studies have shown promising results. For example, the monoclonal neutralizing antibodies MEDI4893 (suvratoxumab) and AR-301 have entered phase 3 trials for the prevention of *Staphylococcus aureus* infections, showing promise in reducing mortality associated with PF-related sepsis [41]. These therapies highlight the potential for translation into routine clinical practice.

Furthermore, research into regulatory processes governing virulence gene expression confirms the value of targeting virulence factors as part of combination therapy. This method utilizes small molecules, such as peptides, to inhibit global regulators like the accessory gene regulator (Agr) in *Staphylococcus aureus*, which controls biofilm formation and toxin production [42]. Specifically, RNAIII, a stable regulatory RNA within the Agr system, has been identified as a key regulator of virulence factors. By inhibiting RNAIII, toxins and other virulence factors can be downregulated, offering a potential strategy for combating *Staphylococcus aureus* infections [42]. In a *Staphylococcus aureus* model, the combination of RNA-III-inhibiting peptide with antibiotics showed improved wound healing and reduced mortality compared to antibiotic therapy alone [42]. Such findings support the notion that targeting virulence factors alongside traditional antimicrobial therapy may enhance the overall management of sepsis in critically ill patients, particularly those with severe complications such as purpura fulminans.

Antimicrobial Stewardship Interventions

Antimicrobial stewardship is paramount in the critical care management of purpura fulminans, where early broad-spectrum antimicrobial therapy is necessary to control infection. Stewardship programs aim to optimize antimicrobial use by ensuring timely de-escalation and promoting narrow-spectrum agents once pathogen identification is achieved [43,44]. In ICU settings, where resistant organisms such as MRSA pose significant threats, stewardship efforts are particularly vital in balancing the urgent need for empiric therapy with the prevention of antimicrobial resistance [43]. The challenge in critical care lies in the urgency of initiating empiric therapy, which can complicate efforts to minimize broad-spectrum antibiotic use. However, stewardship programs emphasize the importance of de-escalation, guided by rapid diagnostic tests such as PCR and mass spectrometry, which can quickly identify pathogens and guide targeted therapy [43]. The use of electronic tools for real-time monitoring of antibiotic use, coupled with multidisciplinary collaboration among infectious disease specialists, pharmacists, and intensivists, is essential for successful stewardship in the ICU.

Research supports the effectiveness of stewardship interventions in reducing unnecessary antibiotic use and hospital-acquired infections. For instance, Pickens and Wunderink reported that stewardship programs in critical care settings led to significant reductions in antibiotic use without compromising patient safety,reinforcing the value of such

programs in improving outcomes for patients with purpura fulminans [43]. The continued advancement of stewardship tools and practices will be key to ensuring that antimicrobial therapies remain effective and that resistant pathogens do not compromise future treatment options.

Future Research Directions

Personalized antimicrobial regimens represent a promising avenue for future research in managing purpura fulminans-associated sepsis. Considering PK and PD principles is essential for optimizing antimicrobial strategies. In critically ill patients, altered drug absorption, distribution, metabolism, and excretion can render standardized dosing regimens ineffective [45]. PK/PD-guided therapy enables dose adjustments based on real-time patient-specific factors, such as renal and hepatic function, ensuring appropriate drug concentrations are reached at infection sites without causing systemic toxicity. This individualized approach is critical in life-threatening conditions like PF, where timely and accurate adjustments to therapy can significantly influence outcomes. Emerging research should explore the use of artificial intelligence and machine learning to refine PK/PD models, potentially enhancing their predictive accuracy for critically ill patients and improving therapeutic efficacy while minimizing the risk of systemic toxicity.

Molecular diagnostic tools are also shaping the future of antimicrobial therapy by enabling rapid pathogen identification and detection of resistance mechanisms [46]. In PF-associated sepsis, where swift initiation of the appropriate therapy is critical, molecular diagnostics offer a significant advantage over traditional culture-based methods, which can delay treatment. Early identification allows clinicians to select targeted antibiotics, reducing reliance on broad-spectrum agents and mitigating associated risks like antimicrobial resistance and increased healthcare costs [47]. However, access to molecular diagnostics is limited in many healthcare settings, impeding the widespread implementation of personalized antimicrobial regimens. Additionally, personalized regimens that consider the patient's microbiome are gaining traction, as preserving the microbiome has been shown to reduce complications such as *Clostridioides difficile* infections [48]. Avoiding these complications has the added benefit of decreasing hospital stays and reducing healthcare costs.

In addition to personalized regimens, there is an urgent need for novel antimicrobial agents to combat multidrug-resistant organisms, which pose a significant challenge in sepsis management. PF-associated pathogens such as *Neisseria meningitidis* and *Streptococcus pneumoniae* are increasingly resistant to standard therapies, highlighting the need for new treatment options. Future research should focus on discovering new antimicrobial compounds and conducting clinical trials to assess their efficacy and safety in critically ill populations. For example, Protein C therapy has shown promise in pediatric sepsis and could be explored further for its synergistic effects with antimicrobials [49]. Additionally, novel agents should be assessed for their ability to target common and rare pathogens associated with PF and their potential to overcome resistance mechanisms. The development of narrow-spectrum agents, designed to target specific bacterial populations without affecting the broader microbiome, is an up-and-coming area of research [50]. Combination therapies, incorporating both traditional antibiotics and novel agents, may offer a comprehensive approach while mitigating resistance development. However, long-term surveillance will be required to assess the impact of these therapies on microbial resistance and patient outcomes.

While personalized antimicrobial regimens and the development of novel agents hold great promise, several limitations must be addressed. The application of personalized antimicrobial therapy in critical care settings depends heavily on the availability of rapid and accurate diagnostic tools, which may be lacking in resource-limited environments, delaying effective treatment. Moreover, the high cost and complexity of developing novel antimicrobial agents can limit their availability, particularly in low- and middle-income countries. As a result, access to these potentially life-saving treatments is not uniform, and research into cost-effective solutions must be prioritized. Additionally, clinicians must be cautious in their approach to antimicrobial therapy, balancing the need for immediate therapeutic needs with the long-term risks of antimicrobial resistance. Further research is needed to identify best practices for antibiotic stewardship in the management of purpura fulminans-associated sepsis to prevent the emergence of resistance while ensuring that patients receive timely and appropriate care.

Conclusion

The management of purpura fulminans-associated sepsis remains a significant challenge in critical care, due to its rapid progression and high mortality rates. Despite recent advances in antimicrobial therapy, effective interventions rely on timely, precise treatment. Combination antimicrobial therapy, personalized dosing regimens guided by pharmacokinetic and pharmacodynamic principles, and the incorporation of rapid diagnostic technologies offers a promising path forward. Additionally, adjunctive therapies targeting bacterial virulence factors, coupled with strong antimicrobial stewardship programs are essential to improving patient outcomes while combating the growing threat of antimicrobial resistance. Continued research into these evolving strategies, alongside the development of novel antimicrobial agents, is essential to refine therapeutic approaches and enhance survival in patients with this life-threatening condition. Ultimately, a multidisciplinary, patient-centered approach will be key to improving care for those affected by purpura fulminans.

References

1. Smith, O. P., & White, B. (1999). Infectious purpura fulminans: Diagnosis and treatment. *British Journal of Haematology*, *104*(2), 202–207. https://doi.org/10.1046/j.1365-2141.1999.01186.x
2. Bollero, D., Stella, M., Gangemi, E. N., Spaziante, L., Nuzzo, J., Sigaudo, G., & Enrichens, F. (2010). Purpura fulminans in meningococcal septicaemia in an adult: a case report. *Annals of burns and fire disasters*, *23*(1), 43–47.
3. Contou, D., Urbina, T., & de Prost, N. (2021). Understanding purpura fulminans in adult patients. *Intensive Care Medicine*, *48*(1), 106–110. https://doi.org/10.1007/s00134-021-06580-2
4. Chalmers, E., Cooper, P., Forman, K., Grimley, C., Khair, K., Minford, A., Morgan, M., & Mumford, A. (2011). Purpura fulminans: Recognition, diagnosis and management. *Archives of Disease in Childhood*, *96*(11), 1066–1071. https://doi.org/10.1136/adc.2010.199919
5. Francis, R. (1990). Acquired purpura fulminans. *Seminars in Thrombosis and Hemostasis*, *16*(04), 310–325. https://doi.org/10.1055/s-2007-1002684.

6. Smith, O., White, B., Vaughan, D., Rafferty, M., Claffey, L., Lyons, B., & Casey, W. (1997). Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. *The Lancet*, *350*(9091), 1590–1593. https://doi.org/10.1016/s0140-6736(97)06356-3
7. Contou, D., Sonneville, R., Canoui-Poitrine, F., Colin, G., Coudroy, R., Pène, F., Tadié, J.-M., Cour, M., Béduneau, G., Marchalot, A., Guérin, L., Jochmans, S., Ehrmann, S., Terzi, N., Préau, S., Barbier, F., Schnell, G., Roux, D., Leroy, O., … de Prost, N. (2018). Clinical spectrum and short-term outcome of adult patients with Purpura Fulminans: A French multicenter retrospective cohort study. *Intensive Care Medicine*, *44*(9), 1502–1511. https://doi.org/10.1007/s00134-018-5341-3
8. Betrosian, A. P., Berlet, T., & Agarwal, B. (2006). Purpura fulminans in sepsis. *The American Journal of the Medical Sciences*, *332*(6), 339–345. https://doi.org/10.1097/00000441-200612000-00006
9. Klifto, K. M., Gurno, C. F., Grzelak, M. J., Seal, S. M., Asif, M., Hultman, C. S., & Caffrey, J. A. (2019). Surgical outcomes in adults with Purpura Fulminans: A systematic review and patient-level meta-synthesis. *Burns & Trauma*, *7*. https://doi.org/10.1186/s41038-019-0168-x
10. Gando, S., Levi, M., & Toh, C.-H. (2016). Disseminated intravascular coagulation. *Nature Reviews Disease Primers*, *2*(1). https://doi.org/10.1038/nrdp.2016.37
11. Colling, M. E., & Bendapudi, P. K. (2018). Purpura fulminans: Mechanism and management of dysregulated hemostasis. *Transfusion Medicine Reviews*, *32*(2), 69–76. https://doi.org/10.1016/j.tmrv.2017.10.001
12. Ventola C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *P & T : a peer-reviewed journal for formulary management*, *40*(4), 277–283.
13. Finland, M. (1957). Editorial. *Circulation*, *15*(5), 641–645. https://doi.org/10.1161/01.cir.15.5.641
14. Podolsky, S. H. (2010). Antibiotics and the social history of the controlled clinical trial, 1950-1970. *Journal of the History of Medicine and Allied Sciences*, *65*(3), 327–367. https://doi.org/10.1093/jhmas/jrq003
15. CDC. Antibiotic Resistance Threats in the United States. (2019). Atlanta, GA: U.S. Department of Health and Human Services, CDC. https://doi.org/10.15620/cdc:82532
16. Klastersky, J., & Georgala, A. (2014). Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. *Critical Reviews in Oncology/Hematology*, *92*(3), 268–278. https://doi.org/10.1016/j.critrevonc.2014.06.002
17. Palmer, M. E., Andrews, L. J., Abbey, T. C., Dahlquist, A. E., & Wenzler, E. (2022). The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A Review. *Frontiers in Pharmacology*, *13*. https://doi.org/10.3389/fphar.2022.888079
18. Rhee, C., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., DelloStritto, L., & Klompas, M. (2024). Trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis in US hospitals. *JAMA Network Open*, *7*(6). https://doi.org/10.1001/jamanetworkopen.2024.18923
19. Mabilat, C., Gros, M. F., Nicolau, D., Mouton, J. W., Textoris, J., Roberts, J. A., Cotta, M. O., van Belkum, A., & Caniaux, I. (2019). Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. *European Journal of Clinical Microbiology & Infectious Diseases*, *39*(5), 791–797. https://doi.org/10.1007/s10096-019-03769-8
20. Bisarya, R., Song, X., Salle, J., Liu, M., Patel, A., & Simpson, S. Q. (2022). Antibiotic timing and progression to septic shock among patients in the ED with suspected infection. *CHEST*, *161*(1), 112–120. https://doi.org/10.1016/j.chest.2021.06.029
21. Charlton, M., & Thompson, J. P. (2019). Pharmacokinetics in sepsis. *BJA Education*, *19*(1), 7–13. https://doi.org/10.1016/j.bjae.2018.09.006
22. Tsai, D., Lipman, J., & Roberts, J. A. (2015). Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. *Current Opinion in Critical Care*, *21*(5), 412–420. https://doi.org/10.1097/mcc.0000000000000229
23. Udy, A. A., Roberts, J. A., & Lipman, J. (2013). Clinical implications of antibiotic pharmacokinetic principles in the critically ill. *Intensive Care Medicine*, *39*(12), 2070–2082. https://doi.org/10.1007/s00134-013-3088-4
24. Gastine, S., Lanckohr, C., Blessou, M., Horn, D., Fobker, M., Bause, D., Hempel, G., & Ellger, B. (2019). Pharmacokinetics of micafungin in critically ill patients. *Scientific Reports*, *9*(1). https://doi.org/10.1038/s41598-019-53093-6
25. Wojtowicz, J. M., & Jones, G. L. (2014). Streptococcus pneumoniae–induced purpura fulminans in a woman with Functional Asplenia. *CJEM*, *16*(04), 339–342. https://doi.org/10.2310/8000.2013.130990
26. Zilberberg, M. D., Shorr, A. F., Micek, S. T., Vazquez-Guillamet, C., & Kollef, M. H. (2014). Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: A retrospective cohort study. *Critical Care*, *18*(6). https://doi.org/10.1186/s13054-014-0596-8
27. Beau, C., Vlassova, N., Sarlangue, J., Brissaud, O., Léauté-Labrèze, C., & Boralevi, F. (2013). Diagnostic value of polymerase chain reaction analysis of Skin biopsies in purpura fulminans. *Pediatric Dermatology*, *30*(6). https://doi.org/10.1111/pde.12181
28. Turnidge, J. (2003). Impact of antibiotic resistance on the treatment of sepsis. *Scandinavian Journal of Infectious Diseases*, *35*(9), 677–682. https://doi.org/10.1080/00365540310015953
29. Shekar, K., Abdul-Aziz, M. H., Cheng, V., Burrows, F., Buscher, H., Cho, Y.-J., Corley, A., Diehl, A., Gilder, E., Jakob, S. M., Kim, H.-S., Levkovich, B. J., Lim, S. Y., McGuinness, S., Parke, R., Pellegrino, V., Que, Y.-A., Reynolds, C., Rudham, S., … Roberts, J. A. (2023). Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation. *American Journal of Respiratory and Critical Care Medicine*, *207*(6), 704–720. https://doi.org/10.1164/rccm.202207-1393oc
30. Moore, L. S., Villegas, M. V., Wenzler, E., Rawson, T. M., Oladele, R. O., Doi, Y., & Apisarnthanarak, A. (2023). Rapid diagnostic test value and implementation in antimicrobial stewardship across low-to-middle and high-income countries: A mixed-methods review. *Infectious*

Diseases and Therapy, *12*(6), 1445–1463. https://doi.org/10.1007/s40121-023-00815-z

31. Garrido, P., Gabaldó-Barrios, X., Pujol-Bajador, I., Fernández, L., Ballester, F., Garrido, R., Cueto, P., Camps, J., & Vallverdú, I. (2023). Assessing the utility of multiplexed polymerase chain reaction in detecting microorganisms causing infections in critically ill patients. *Current Microbiology*, *80*(11). https://doi.org/10.1007/s00284-023-03461-3.
32. Sinha, M., Jupe, J., Mack, H., Coleman, T. P., Lawrence, S. M., & Fraley, S. I. (2018). Emerging technologies for molecular diagnosis of sepsis. *Clinical Microbiology Reviews*, *31*(2). https://doi.org/10.1128/cmr.00089-17.
33. Luethy, P. M., & Johnson, J. K. (2019). The use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the identification of pathogens causing sepsis. *The Journal of Applied Laboratory Medicine*, *3*(4), 675–685. https://doi.org/10.1373/jalm.2018.027318.
34. Qu, J., L, X., Liu, Y., & Wang, X. (2015). Evaluation of procalcitonin, C-reactive protein, interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients. *The Indian journal of medical research*, *141*(3), 315–321. https://doi.org/10.4103/0971-5916.156617.
35. Lee, E.-H., Lee, K.-H., Song, Y.-G., & Han, S.-H. (2022). Discrepancy of C-reactive protein, Procalcitonin and interleukin-6 at hospitalization: Infection in patients with normal C-reactive protein, Procalcitonin and high interleukin-6 values. *Journal of Clinical Medicine*, *11*(24), 7324. https://doi.org/10.3390/jcm11247324.
36. Tuon, F. F., Suss, P. H., Telles, J. P., Dantas, L. R., Borges, N. H., & Ribeiro, V. S. (2023). Antimicrobial treatment of Staphylococcus aureus biofilms. *Antibiotics*, *12*(1), 87. https://doi.org/10.3390/antibiotics12010087.
37. Kumar, A., Safdar, N., Kethireddy, S., & Chateau, D. (2010). A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study. *Critical Care Medicine*, *38*(8), 1651–1664. https://doi.org/10.1097/ccm.0b013e3181e96b91
38. Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012). Combination therapy for treatment of infections with gram-negative bacteria. *Clinical Microbiology Reviews*, *25*(3), 450–470. https://doi.org/10.1128/cmr.05041-11.
39. Strich, J. R., Heil, E. L., & Masur, H. (2020). Considerations for empiric antimicrobial therapy in sepsis and septic shock in an era of antimicrobial resistance. *The Journal of Infectious Diseases*, *222*(Supplement_2). https://doi.org/10.1093/infdis/jiaa221.
40. Clatworthy, A. E., Pierson, E., & Hung, D. T. (2007). Targeting virulence: A new paradigm for antimicrobial therapy. *Nature Chemical Biology*, *3*(9), 541–548. https://doi.org/10.1038/nchembio.2007.24.
41. Dehbanipour, R., & Ghalavand, Z. (2022). Anti-virulence therapeutic strategies against bacterial infections: Recent advances. *Germs*, *12*(2), 262–275. https://doi.org/10.18683/germs.2022.1328.
42. Ahmad-Mansour, N., Loubet, P., Pouget, C., Dunyach-Remy, C., Sotto, A., Lavigne, J.-P., & Molle, V. (2021). Staphyl ococcus aureus toxins: An update on their pathogenic properties and potential treatments. *Toxins*, *13*(10), 677. https://doi.org/10.3390/toxins13100677.
43. Pickens, C. I., & Wunderink, R. G. (2019). Principles and practice of antibiotic stewardship in the ICU. *Chest*, *156*(1), 163–171. https://doi.org/10.1016/j.chest.2019.01.013.
44. Lakbar, I., De Waele, J. J., Tabah, A., Einav, S., Martin-Loeches, I., & Leone, M. (2020). Antimicrobial de-escalation in the ICU: From recommendations to level of evidence. *Advances in Therapy*, *37*(7), 3083–3096. https://doi.org/10.1007/s12325-020-01390-2.
45. Roberts, D. J., & Hall, R. I. (2013). Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. *Expert Opinion on Drug Metabolism & Toxicology*, *9*(9), 1067–1084. https://doi.org/10.1517/17425255.2013.799137.
46. Vasala, A., Hytönen, V. P., & Laitinen, O. H. (2020). Modern tools for rapid diagnostics of antimicrobial resistance. *Frontiers in Cellular and Infection Microbiology*, *10*. https://doi.org/10.3389/fcimb.2020.00308.
47. Perez, K. K., Olsen, R. J., Musick, W. L., Cernoch, P. L., Davis, J. R., Land, G. A., Peterson, L. E., & Musser, J. M. (2012). Integrating Rapid Pathogen Identification and antimicrobial stewardship significantly decreases hospital costs. *Archives of Pathology & Laboratory Medicine*, *137*(9), 1247–1254. https://doi.org/10.5858/arpa.2012-0651-oa.
48. Ratiner, K., Ciocan, D., Abdeen, S. K., & Elinav, E. (2023). Utilization of the microbiome in personalized medicine. *Nature Reviews Microbiology*, *22*(5), 291–308. https://doi.org/10.1038/s41579-023-00998-9.
49. Eliwan, H., Omer, M., McKenna, E., Kelly, L. A., Nolan, B., Regan, I., & Molloy, E. J. (2022). Protein C pathway in paediatric and neonatal sepsis. *Frontiers in Pediatrics*, *9*. https://doi.org/10.3389/fped.2021.562495.
50. Yang, B., Fang, D., Lv, Q., Wang, Z., & Liu, Y. (2021). Targeted therapeutic strategies in the battle against pathogenic bacteria. *Frontiers in Pharmacology*, *12*. https://doi.org/10.3389/fphar.2021.673239.